Frequently Asked Questions About QUTENZA

No, QUTENZA is only available through a Specialty Distributor or a Specialty Pharmacy. For a full list of our Specialty Distributors and Specialty Pharmacies, click here. Please call QUTENZA Customer Support at 877-900-6479 for more information.

QUTENZA is a prescription product that is prescribed and administered by a healthcare professional.

QUTENZA is sold by Averitas Pharma as a prescription drug in the United States. As such, we are unable to address your inquiry.

Patients can call QUTENZA Customer Support at 877-900-6479 for more information.

Requirements vary for different payers and plans. CoPilot provides dedicated resources to complete a full benefits investigation to evaluate all financial support options and gain approval for the procedure. QUTENZA Reimbursement Support Services can be reached at 855-802-8746, Monday through Friday, 9 AM to 7 PM ET, or visit MyQutenzaConnect.com.

Yes. Eligible patients may pay as little as $25 for QUTENZA if they are commercially insured and 18 years of age or older. Click here for details.

QUTENZA is manufactured for Averitas Pharma, Inc., by Lohmann Therapie-Systeme AG (LTS), Andernach, Germany.

QUTENZA is distributed through our Specialty Distributors. For a full list of these Specialty Distributors, click here.

At this time, we do not offer samples.

There are no other active ingredients in QUTENZA. The inactive ingredients in QUTENZA are diethylene glycol monoethyl ether (DGME, also called Transcutol), dimethicone, ethyl cellulose, polyester film, silicone adhesive, and white ink. The Cleansing Gel, which is supplied with QUTENZA, has the following ingredients: butylated hydroxyanisole, carbomer copolymer, edetate disodium, polyethylene glycol, purified water, and sodium hydroxide.¹

QUTENZA can be used alone or in combination with other oral medications for pain.¹

In the PHN clinical trials, the most common adverse reactions were application site pain, erythema, pruritus, and papules. QUTENZA is to be used only on dry, intact (unbroken) skin. While there are no contraindications for QUTENZA use in this patient population, the assessment of an individual patient's eligibility for treatment based on previous or current dermatological conditions or diseases needs to be made by the treating healthcare professional.¹

The most common adverse reactions (≥5% and > control group) in all controlled clinical trials are application site erythema, application site pain, and application site pruritus.¹

Warnings and Precautions¹

• Severe Irritation: Whether applied directly or transferred accidentally from other surfaces, capsaicin can cause severe irritation of eyes, mucous membranes, respiratory tract, and skin to the healthcare professional, patients, and others. Do not use near eyes or mucous membranes, including face and scalp. Take protective measures, including wearing nitrile gloves and not touching items or surfaces that the patient may also touch. Flush irritated mucous membranes or eyes with water and provide supportive medical care for shortness of breath. Remove affected individuals from the vicinity of QUTENZA. Do not re-expose affected individuals to QUTENZA if respiratory irritation worsens or does not resolve. If skin not intended to be treated comes into contact with QUTENZA, apply Cleansing Gel and then wipe off with dry gauze. Thoroughly clean all areas and items exposed to QUTENZA and dispose of properly. Because aerosolization of capsaicin can occur with rapid removal, administer QUTENZA in a well-ventilated area, and remove gently and slowly, rolling the adhesive side inward.
• Application-Associated Pain: Patients may experience substantial procedural pain and burning upon application and following removal of QUTENZA. Prepare to treat acute pain during and following application with local cooling (e.g., ice pack) and/or appropriate analgesic medication.
• Increase in Blood Pressure: Transient increases in blood pressure may occur with QUTENZA treatment. Monitor blood pressure during and following treatment procedure and provide support for treatment-related pain. Patients with unstable or poorly controlled hypertension, or a recent history of cardiovascular or cerebrovascular events, may be at an increased risk of adverse cardiovascular effects. Consider these factors prior to initiating QUTENZA treatment.
• Sensory Function: Reductions in sensory function (generally minor and temporary) have been reported following administration of QUTENZA. All patients with sensory deficits should be assessed for signs of sensory deterioration or loss prior to each application of QUTENZA. If sensory loss occurs, treatment should be reconsidered.

While patient results may vary, in the clinical studies, some patients experienced a decrease in pain as early as 2 days which persisted throughout the study duration. For some patients, relief may take a few weeks.¹

Patients should be able to drive themselves home as QUTENZA doesn't impair patients. However, depending on the area treated, on the shoulder, chest, or breast area, for example, patients may be sensitive to the safety belt. Make sure patients are aware of this if they are driving, and take measures to add additional padding between the belt and the treatment area.

It's quite common for the area to remain sensitive to heat for a few days after application. Patients may also continue to feel some burning or stinging sensation. These effects are commonly seen with QUTENZA patients and most of the application reactions will go away on their own and only last a short time.¹

QUTENZA should not be applied to the face, eyes, mouth, nose, or scalp so that risk of exposure to the eyes or mucous membranes is avoided.¹

The recommended dose of QUTENZA is a single, 60-minute procedure of up to four topical systems. Treatment with QUTENZA may be repeated every three months or as warranted by the return of pain (not more frequently than every three months).¹

Use of pre-treatment topical anesthetic is optional at the discretion of the healthcare provider who is administering treatment.

Even following use of a local anesthetic prior to administration of QUTENZA, patients may experience substantial procedural pain. Prepare to treat acute pain during and following the application procedure with local cooling (such as an ice pack) and/or appropriate analgesic medication. Based upon experience and feedback from users, local cooling packs may be sufficient; however, each patient is different.

Yes. Please refer to Section 2.3 Instructions for Use in the full Prescribing Information.